Targeting glycosphingolipids for cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Glycobiology

Background:

• Aberrant expression of glycosphingolipids (GSLs) is a characteristic feature of cancer cells and the tumor microenvironment.
• The precise role of GSLs in tumor progression is not fully understood, but GSL-targeted immunotherapies are gaining traction.
• GD2, a disialoganglioside, is found in neuroectodermal tumors, while Globo H ceramide (GHCer) is prevalent in epithelial cancers.

Purpose of the Study:

• To review the biology of GD2 and GHCer GSLs in cancer.
• To discuss the clinical development and efficacy of GD2-targeted immunotherapeutics, such as dinutuximab.
• To examine ongoing clinical trials for Globo H-targeted immunotherapies and their potential for novel cancer therapeutics.

Main Methods:

• Literature review summarizing recent advances in GD2 and GHCer biology.
• Analysis of clinical development of dinutuximab, a GD2-specific antibody.
• Review of ongoing clinical trials for Globo H-targeted immunotherapeutics.

Main Results:

• Dinutuximab is an approved GD2-targeted immunotherapeutic agent for neuroblastoma, with ongoing strategies to enhance its efficacy.
• Several clinical trials are evaluating Globo H-targeted immunotherapeutics for various epithelial cancers.
• These studies provide a strong scientific basis for targeting GSLs in cancer treatment.

Conclusions:

• Targeting GSLs like GD2 and GHCer represents a promising strategy in cancer immunotherapy.
• The development of GSL-specific antibodies and other immunotherapeutics offers new avenues for cancer treatment.
• Further research and clinical trials are essential for optimizing GSL-targeted therapies and designing novel anticancer agents.